NasdaqGS:REGNBiotechs
Regeneron Pharmaceuticals (NasdaqGS:REGN) Secures US$80 Million Deal For GLP-1/GIP Drug Rights
Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094. Concurrently, interim results from their Phase 2 COURAGE trial revealed continuing investigations of semaglutide and trevogrumab combinations, emphasizing regulatory and market complexities. Despite these developments, Regeneron’s share price fell by 17% over the past week, contrasting sharply with a 2%...